LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


Innate Pharma Announces Positive IPH21 Phase 1 AML Trial Results That Support Further Studies


« Back to News


-Phase 2 AML Study to Begin by Year End-


Report is Available for Download at: www.lifesciadvisors.com/clients/innate

Innate Pharma (Euronext: IPH) is a leading company in the innate immunology space that just announced positive Phase 1 results for IPH21, the Company’s lead candidate partnered with Bristol-Myers Squibb (NYSE: BMY). The study showed that there was a clear relationship between IPH21 dose, blood concentration, and KIR receptor occupancy. These results support the soon-to-be initiated Phase 2 AML study with IPH21 in elderly AML patients in complete remission.

The aim of the Phase 1 trial was to evaluate the safety, tolerability, and pharmacological profile of IPH21 in elderly AML patients in complete remission after induction and consolidation treatment. The trial has a dose-escalation protocol with seven dose levels ranging from 0.0003 to 3 mg/kg with 3 patients per dose level. Each patient was administered a single dose. The study objective was to determine a safe and pharmacologically active dose. 23 patients were enrolled into the study with a median age of 71.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design